2018-19 Section 7-Neoplastic and Inflammatory Diseases of the Head and Neck eBook

Suárez C, Barnes L, Silver CE, et al. Cervical lymph node metastasis in adenoid cystic carcinoma of oral cavity and oropharynx: a collective international review. Auris Nasus Larynx . 2016; 43(5):477- 484. EBM level 4................................................................................................................................26-33 Summary : This article essentially presents a literature review and expert opinion written by some of the most notable investigators in the field of salivary gland cancers. The authors attempt to establish guidelines for neck dissection and management of adenoid cystic carcinoma of the oral cavity and oropharynx. B. Chemotherapy, immunotherapy for salivary cancer Amini A, Waxweiler TV, Brower JV, et al. Association of adjuvant chemoradiotherapy vs radiotherapy alone with survival in patients with resected major salivary gland carcinoma: data from the National Cancer Data Base. JAMA Otolaryngol Head Neck Surg . 2016; 142(11):1100-1110. EBM level 3.........................................................................................................................................34-44 Summary : This study is a retrospective analysis of 2210 patients with resected major salivary gland cancers from the National Cancer Data Base. The authors analyzed the difference in survival between patients who had chemoradiation versus radiation postoperatively. There was no survival advantage conferred with the addition of chemotherapy. Cheraghlou S, Kuo P, Mehra S, et al. Adjuvant therapy in major salivary gland cancers: analysis of 8580 patients in the National Cancer Database. Head Neck . 2018; 40(7):1343-1355. EBM level 3...................................................................................................................................................45-57 Summary : This study evaluated 8580 patients with salivary gland cancers in the National Cancer Data Base. Adjuvant radiation improved survival in salivary gland cancers with adverse features at any stage. However, the addition of chemotherapy did not improve outcomes in late-stage disease with adverse features. i. Changes in staging Eggermont AMM, Dummer R. The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients. Eur J Cancer . 2017; 86:101-105. EBM level 1...................................................................................................58-62 Summary : This article reviews the major clinical trials for melanoma including studies of interferon, ipilimumab, nivolumab, pembrolizumab, and dabrafenib/trametinib. Nivolumab and the combination of dabrafenib/trametinib have shown the best results. Meta-analysis of the interferon studies shows that only patients with ulceration benefit from interferon. A. Melanoma

II. Skin